Induction of Apoptosis and Down-Regulation of Bcl-XL in Cancer Cells by a Novel Small Molecule, 2[[3-(2,3-Dichlorophenoxy)propyl]amino]ethanol

Cancer Research

Volumn 64, Issue 3, 2004, Pages 1110-1113

  Wu, Shuhong ^a   Zhu, Hongbo ^a   Gu, Jian ^a   Zhang, Lidong ^a   Teraishi, Fuminori ^a   Davis, John J ^a,b   Jacob, Dietmar A ^a   Fang, Bingliang ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[3 (2,3 DICHLOROPHENOXY)PROPYL]AMINO]ETHANOL; 2,4 DICHLOROPHENOXYACETIC ACID; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CYTOCHROME C; DIMETHYL SULFOXIDE; FLUOROURACIL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BCL XL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME DEGRADATION; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL DIVISION; CELL LINE, TUMOR; CHLOROBENZENES; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ETHANOLAMINES; FIBROBLASTS; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION;

EID: 0842304280     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2790     Document Type: Article

References (15)

1. World Health Organization. World Cancer Report. Lyon: IARC Press, 2003.
2. Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer research. Science (Wash. DC), 287: 1969-1973, 2000.
3. Amundson, S. A., Myers, T. G., Scudiero, D., Kitada, S., Reed, J. C., and Fomace, A. J., Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res., 60: 6101-6110, 2000.
4. Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T., and Thompson, C. B. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell, 91: 627-637, 1997.
5. L prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor α-induced apoptosis. Mol. Cell. Biol., 20: 5680-5689, 2000.
6. Minn, A. J., Rudin, C. M., Boise, L. H., and Thompson, C. B. Expression of Bcl-XL can confer a multidrug resistance phenotype. Blood, 86: 1903-1910, 1995.
7. Kharbanda, S., Pandey, P., Schofield, L., Israels, S., Roncinske, R., Yoshida, K., Bharti, A., Yuan, Z. M., Saxena, S., Weichselbaum, R., Nalin, C., and Kufe, D. Role for Bcl-xL as an inhibitor of cytosolic cytochrome c accumulation in DNA damage-induced apoptosis. Proc. Natl. Acad. Sci. USA, 94: 6939-6942, 1997.
8. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science (Wash. DC), 290: 989-992, 2000.
9. Zhang, L., Gu, J., Lin, T., Huang, X., Roth, J. A., and Fang, B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther., 9: 1262-1270, 2002.
10. Gu, J., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J. A., and Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res., 60: 5359-5364, 2000.
11. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-42, 1994.
12. Lin, T., Gu, J., Zhang, L., Huang, X., Stephens, L. C., Curley, S. A., and Fang, B. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effect on primary human hepatocytes. Cancer Res., 62: 3620-3625, 2002.
13. Tarbit, M. H., and Berman, J. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem. Biol., 2: 411-416, 1998.
14. Lin, J. H., and Lu, A. Y. Role of pharmacokinetics and metabolism in drug discovery and development. Pharm. Rev., 49: 403-449, 1997.
15. Prentis, R. A., Lis, Y., and Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharm., 25: 387-396, 1998.